Compare GLAD & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLAD | AURA |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.2M | 419.5M |
| IPO Year | N/A | 2021 |
| Metric | GLAD | AURA |
|---|---|---|
| Price | $19.02 | $7.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.33 | $20.00 |
| AVG Volume (30 Days) | 161.5K | ★ 726.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.54 | $4.73 |
| 52 Week High | $29.50 | $9.54 |
| Indicator | GLAD | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 51.70 |
| Support Level | $18.84 | $5.94 |
| Resistance Level | $19.44 | $7.68 |
| Average True Range (ATR) | 0.44 | 0.47 |
| MACD | -0.09 | -0.10 |
| Stochastic Oscillator | 21.10 | 20.37 |
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.